307 related articles for article (PubMed ID: 23650288)
1. The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension.
Fan YF; Zhang R; Jiang X; Wen L; Wu DC; Liu D; Yuan P; Wang YL; Jing ZC
Cardiovasc Res; 2013 Aug; 99(3):395-403. PubMed ID: 23650288
[TBL] [Abstract][Full Text] [Related]
2. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study.
Jing ZC; Yu ZX; Shen JY; Wu BX; Xu KF; Zhu XY; Pan L; Zhang ZL; Liu XQ; Zhang YS; Jiang X; Galiè N;
Am J Respir Crit Care Med; 2011 Jun; 183(12):1723-9. PubMed ID: 21471085
[TBL] [Abstract][Full Text] [Related]
3. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
4. [Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].
Kiliçkesmez K; Küçükoğlu MS
Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():16-8. PubMed ID: 20819751
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
6. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study.
Jing ZC; Jiang X; Wu BX; Xu XQ; Wu Y; Ma CR; Wang Y; Yang YJ; Pu JL; Gao W
Heart; 2009 Sep; 95(18):1531-6. PubMed ID: 19549620
[TBL] [Abstract][Full Text] [Related]
7. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.
Mawatari E; Hongo M; Sakai A; Terasawa F; Takahashi M; Yazaki Y; Kinoshita O; Ikeda U
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):594-600. PubMed ID: 17581214
[TBL] [Abstract][Full Text] [Related]
8. Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil.
Schroll S; Sebah D; Wagner M; Popara V; Pfeifer M; Blumberg F
Respir Physiol Neurobiol; 2013 Mar; 186(1):61-4. PubMed ID: 23246673
[TBL] [Abstract][Full Text] [Related]
9. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
[TBL] [Abstract][Full Text] [Related]
10. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension.
Aizawa K; Hanaoka T; Kasai H; Kogashi K; Kumazaki S; Koyama J; Tsutsui H; Yazaki Y; Watanabe N; Kinoshita O; Ikeda U
Hypertens Res; 2006 Feb; 29(2):123-8. PubMed ID: 16755146
[TBL] [Abstract][Full Text] [Related]
11. [Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].
Sakuma M; Shirato K
Nihon Rinsho; 2008 Nov; 66(11):2157-61. PubMed ID: 19051736
[TBL] [Abstract][Full Text] [Related]
12. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.
Nishimura T; Vaszar LT; Faul JL; Zhao G; Berry GJ; Shi L; Qiu D; Benson G; Pearl RG; Kao PN
Circulation; 2003 Sep; 108(13):1640-5. PubMed ID: 12963647
[TBL] [Abstract][Full Text] [Related]
14. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
[TBL] [Abstract][Full Text] [Related]
15. Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension.
Karasu-Minareci E; Ozbudak IH; Ozbilim G; Sadan G
ScientificWorldJournal; 2012; 2012():718279. PubMed ID: 22649315
[TBL] [Abstract][Full Text] [Related]
16. Vascular dysfunction induced by hypochlorite is improved by the selective phosphodiesterase-5-inhibitor vardenafil.
Radovits T; Arif R; Bömicke T; Korkmaz S; Barnucz E; Karck M; Merkely B; Szabó G
Eur J Pharmacol; 2013 Jun; 710(1-3):110-9. PubMed ID: 23623933
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
Zheng Y; Ma H; Hu E; Huang Z; Cheng X; Xiong C
J Cardiovasc Pharmacol; 2015 Nov; 66(5):504-14. PubMed ID: 26535780
[TBL] [Abstract][Full Text] [Related]
19. Role of oxidative stress, inflammation, nitric oxide and transforming growth factor-beta in the protective effect of diosgenin in monocrotaline-induced pulmonary hypertension in rats.
Ahmed LA; Obaid AA; Zaki HF; Agha AM
Eur J Pharmacol; 2014 Oct; 740():379-87. PubMed ID: 25062790
[TBL] [Abstract][Full Text] [Related]
20. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure.
Yin J; Kukucka M; Hoffmann J; Sterner-Kock A; Burhenne J; Haefeli WE; Kuppe H; Kuebler WM
Circ Heart Fail; 2011 Mar; 4(2):198-206. PubMed ID: 21216837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
